$56 Profit
CURLong Stock
Entry comments: Company announced that additional safety, efficacy and tolerability data from its exploratory Phase 2 clinical trial examining the efficacy of NSI-189. Entered because the stock was making higher lows, high volume, and I was comfortable with the entry.
Exit comments: I was working last night and could not sell into the strength around $3. Today I saw the dip, but I figured it would stabilize around 2.40 and go back up on Thursday but it dipped too far down for my comfort level. I lost a good amount of profit, and I didn't want to lose anymore so I exited.
Date | Price | |
---|---|---|
Entry | 12/4/2017 | 1.98 |
Exit | 12/5/2017 | 2.202 |
- Total Views52
- Position Size250
- Percentage11.21%
Copy and paste the following into your page or blog. If using WordPress, you must paste this in the HTML tab only: